Maven Securities’s Aurinia Pharmaceuticals AUPH Stock Holding History

Maven Securities’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-50,000	Closed	-$813K	–	605
2020 Q2	$813K	Buy	+50,000	New	+$801K	0.06%	237
2020 Q1	–	Sell	-214,673	Closed	-$4.37M	–	318
2019 Q4	$4.37M	Buy	+214,673	New	+$1.98M	0.4%	45

Other funds holding AUPH

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Maven Securities's AUPH Position: Q3 2020 in Review

Maven Securities sold out of Aurinia Pharmaceuticals (AUPH) in Q3 2020, closing a stake of 50,000 shares — an estimated $813K sold.

Maven Securities first reported a position in AUPH in Q4 2019 and held it in 2 quarters. The position peaked at $4.37M in Q4 2019. 145 funds tracked by Wall St. Rank hold AUPH as of Q3 2020.

Maven Securities reported no remaining Aurinia Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Maven Securities sold 50,000 Aurinia Pharmaceuticals shares in Q3 2020, an estimated $813K.
Maven Securities first reported a position in Aurinia Pharmaceuticals in Q4 2019 and held it in 2 quarters.
Maven Securities's Aurinia Pharmaceuticals position peaked at $4.37M in Q4 2019.
145 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2020.

Based on Maven Securities's 13F filing for Q3 2020, filed 13 Nov 2020.